Literature DB >> 25816754

Peripheral expression of hepcidin gene in Egyptian β-thalassemia major.

Azza Aboul-Enein1, Amal El-Beshlawy2, Mona Hamdy2, Iman Shaheen1, Zainab El-Saadany1, Ahmed Samir3, Hala Abd El-Samie1.   

Abstract

Iron overload is the major cause of morbidity and mortality in transfusion dependent β-thalassemia major patients. There is a sophisticated balance of body iron metabolism of storage and transport which is regulated by several factors including the peptide hepcidin. Hepcidin is the main iron regulatory molecule; it is secreted mainly by the liver and other tissues including monocytes and lymphocytes. Expression of hepcidin in such cells is unclear and has been studied in few reports with controverted result. Peripheral expression of hepcidin was measured using quantitative real time PCR (qRT-PCR) in 50 β-thalassemia major patients, in addition to 20 healthy volunteers as a control group. Hepcidin levels in β-thalassemia major patients showed statistically significant decrease in comparison to the control group, and was correlated to cardiac iron stores (T2*). However, hepcidin level was not different among the patients according to the HCV status or whether splenectomized or not. In conclusion; peripheral expression of hepcidin, in iron overloaded β-thalassemia major patients, is a reflection of hepatic expression. It can be used as a molecular predictor for the severity of cardiac iron overload and can be used as a future target for therapy in β-thalassemia major patients.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiac iron (T2*); Hepcidin expression; qRT-PCR; β-Thalassemia

Mesh:

Substances:

Year:  2015        PMID: 25816754     DOI: 10.1016/j.gene.2015.03.048

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  1 in total

1.  Hepcidin in non-alcoholic fatty liver disease regulated by the TLR4/NF-κB signaling pathway.

Authors:  Wei Chen; Xiaowei Wang; L I Huang; B O Liu
Journal:  Exp Ther Med       Date:  2015-11-17       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.